AqVida uses social media to promote new partnerships

Hamburg, Germany: – Innovative German oncology laboratory AqVida is focusing to expand its activities. After signing a licensing agreement with a strong partner to cover several CEE countries, AqVida is intensifying its activities in Southern European area e.g. through its own network and social media [i.e. Twitter – @oncoaqvida].

In mid May, AqVida tweeted: “We would like to connect with a strong licensing agent in Italy to promote our licensing activities #oncology”. This followed successful use of Twitter and LinkedIn to find new collaborators in Asia and Africa.

Innovative partnering models

AqVida is using this 21st century networking model to promote partnering models that are similarly innovative, with product licenses that include supply binding along with Development, Co-Development and Regulatory Services arrangements. Moreover, AqVida provides a “Just-In-Time” delivery infrastructure, by keeping inventory of bulk [unlabeled vials] in its German warehouse. All these are designed to promote flexibility, quick response and short-lead times.”

“We are looking to connected with partners with in-licensing interests, while out licensing in ways that uphold our own ‘quality is core’ principles,” said AqVida’s Commercial Director, Jürgen Lehmberg.

New capacity

“While our core focus is on development, manufacturing and licensing into regulated European markets, we are also looking to reach out to emerging semi-/non-regulated markets,” explained Jürgen Lehmberg.

AqVida is specialized and fully dedicated to development, manufacturing and licensing oncology finished dosage forms (FDFs).
Celebrating its tenth anniversary this year, AqVida has been growing rapidly in recent years, with new capacity shortly to come on stream from a new novel manufacturing site in Germany optimized for a zero loss production of high value products in the oncology field including e.g. antibody drug conjugates (ADCs). This will increase the company’s capacity for outsourced development of new generics and biosimilars.

About AqVida

AqVida GmbH is a German pharmaceutical company specializing in development, fast-track registration, licensing and/or distribution of finished dosage forms focused on the oncology sector. It has developed a portfolio of medicines for treating the most common types of cancer.
AqVida’s expertise in the development, registration and supply of generic oncology products and biosimilars has made the company a reliable partner in the pharmaceutical industry, providing an extra-ordinary flexibility.

AqVida works alongside some of the major companies in the market of oncology products. Together with its partners AqVida has achieved substantial development and growth with its oncology portfolio.

After having developed and launched several oncology parenteral forms such as e.g. Paclitaxel, Docetaxel and Oxaliplatin, AqVida and its partner company, Benavis, have started development work on the ‘tinib’ series of molecular targeted anti-cancer molecules, i.e. Imatinib (generic version of Glivec® / Gleevec®). AqVida is also developing other molecular targeted anti-cancer molecules, such as Sunitinib (generic version of Sutent®).